QQ客服 官方微博 反馈留言

	CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
	Shi, Yuankai; Li, Jin; Xu, Jianming; Sun, Yan; Wang, Liwei; Cheng, Ying; Liu, Wei; Sun, Guoping; Chen, Yigui; Bai, Li
刊名	CANCER COMMUNICATIONS
	2019
卷号	39
关键词	CMAB009 Cetuximab Irinotecan Second-line mCRC EGFR KRAS Immunogenicity Fluoropyrimidine Oxaliplatin failure
ISSN号	2523-3548
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3598656
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Shi, Yuankai,Li, Jin,Xu, Jianming,et al. CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial[J]. CANCER COMMUNICATIONS,2019,39.
APA	Shi, Yuankai.,Li, Jin.,Xu, Jianming.,Sun, Yan.,Wang, Liwei.,...&Ouyang, Xuenong.(2019).CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.CANCER COMMUNICATIONS,39.
MLA	Shi, Yuankai,et al."CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial".CANCER COMMUNICATIONS 39(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。